PDUFA IV Information Technology Plan. Armando Oliva, M.D. Deputy Director for Bioinformatics Office of Critical Path Programs FDA

Similar documents
Office of the Chief Information Officer (HFA 080) Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857

Now We are Getting to the Hard Parts: An Analysis Files Perspective

CDISC Standards Webinar Latest Updates and Additions 31 Jan 2013

PROGRAM INTERCHANGE Japan

Introduction to China CDISC Coordinating Committee (C3C) February 2014

Site-Less CRO Model and esource: Framework for Action

Japanese submission/approval processes from programming perspective Ryan Hara, Novartis Pharma AG, Basel, Switzerland

Data Elements: Bridging Clinical & Research Data

CDISC 2012 Annual Report TEAMWORK.... with collaboration there is strength.

Beijing esubmission Packages

HL7 capabilities for working with GS1

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA

A guide to PDUFA V. Focus US update. Regulatory Rapporteur Vol 9, No 11, November 2012

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare

CDISC Asia-Pacific/Japan Interchange CDISC Standards: Transcending Geographic Lines for the Betterment of Clinical Research

HL7 RCRIM Regulated Product Submissions

CDER Small Business and Industry Assistance (SBIA)

Definition of Meaningful Use of Certified EHR Technology for Hospitals Approved by the HIMSS Board of Directors April 24, 2009

Guidance for Industry

PDUFA V. New Review Program for NME NDAs and Original BLAs. Enhanced Communications with FDA and Sponsors. Beth Duvall

S t r e n g t h t h r o u g h C o l l a b o r a t i o n

JOINT CODE OF PRACTICE FOR RESEARCH

FDA Reauthorization Act of 2017 (FDARA)

Paper PO 53. Reporting of treatment emergent adverse events based on pooled data Analysis or Country Specific Submissions: A case study

2014 CDISC International Interchange Conference Program

Study Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting

Postmarketing Drug Safety and Inspection Readiness

Registries for Evaluating Patient Outcomes: A User s Guide

Confronting the Challenges of Rare Disease:

Delivering a quality CDISC compliant accelerated submission using an outsourced model Mei Dey, AstraZeneca (USA) Diane Peers, AstraZeneca (UK)

Quality Management Plan

<Insert Picture Here> Some Background and What You Should Know and Do Now to Prepare

Verification of Specifications Data Flow Diagrams (DFD) Summary. Specification. Miaoqing Huang University of Arkansas Spring / 28

Clinical Research Professionals

Duke-Margolis Center: Overview And High Priority Projects in Biomedical Innovation and Payment

Sample Policy and Procedure on Prohibition on Distributing Medical Marijuana

Open DFARS Cases as of 5/10/2018 2:29:59PM

Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO

- j / <-, rei BOARD OF AIRPORT COMMISSIONERS. e:t. Flin hief Executive Officer REPORT TO THE

IMDRF FINAL DOCUMENT. Title: Strategic Assessment of Electronic Submission Messaging Formats

1. Introduction, purpose of this Standard Operating Procedure (SOP)

Defense Federal Acquisition Regulation Supplement: Micro- AGENCY: Defense Acquisition Regulations System, Department of

$7.34 billion $7.72 billion 5.2 percent. $325 million $450 million 38 percent

FDA Information Day: who should attend. Detailed Update on the Latest Information for ICSR and IDMP. Individual Case Safety Reports

GDUFA II: Requests for Reconsideration

GOOD LABORATORY PRACTICES (GLP) OVERVIEW

Slide 1. Slide 2. Slide 3. Component 9 - Networking and Health Information Exchange. Objectives. EHR System (EHR-S)

UNC Lineberger Comprehensive Cancer Center. Data and Safety Monitoring Plan

Establishment of the FDA Office of Patient Affairs

FDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice

Role and Vision of PMDA

Butchers Arms Headington (

DEPARTMENT OF ENVIRONMENTAL PROTECTION Policy Office. Policy for Development and Publication of Technical Guidance

Request for Proposal PROFESSIONAL AUDIT SERVICES. Luzerne-Wyoming Counties Mental Health/Mental Retardation Program

HL7 A Quick Introduction

Continuity of Care Record (CCR)

LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.

The National Drug Shortage inems. Objectives 12/18/2012. Who regulates what? How do they potentially impact EMS?

STANFORD CANCER INSTITUTE 2019 CANCER INNOVATION AWARDS Full Proposal Submission Guidelines

IPEC- Americas Ongoing Projects

41 USC NB: This unofficial compilation of the U.S. Code is current as of Jan. 4, 2012 (see

Eastern Michigan University. Office of Research Development and Administration (ORDA) Externally Sponsored Projects Procedures

BIMO Program Update an operational perspective

Chapter 13 Section 1

Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes

Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015

Pharmacovigilance & Managed Care Pharmacy. Issues for Medication Safety in Korea

An Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule

October, 2016 Pediatric Heart Network Policy Manual

Effective Date: 11/09 Policy Chronicle:

Progress Report in 2016

Data Acceptance Panel Discussion

FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV

Current status on Adverse Event Reporting in Japan

Registration of Clinical Trials: Background and Implementation

Acute Coronary Syndromes (ACS) Provincial Orders Dissemination. Final Evaluation Report

Public Health Subcommittee

Medical Privacy and Business Process Design

The Medicare Local Coverage Determination Process and Clinical Trials

Using Healthy People 2020 to Improve Population Health

Complaint Handling and Medical Device Reporting (MDRs)

ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY

36 th Annual Meeting Preconference Workshop P4 Handout

Adirondack Medical Home Pilot Overview. Dennis Weaver MD MBA November 2, 2010

DESTRUCTION AND RETENTION OF CLINICAL HEALTH RECORDS POLICY

E-Health Information Campaign Shapes Pharmaceutical Regulation

1. Introduction, purpose of this Standard Operating Procedure (SOP)

Report No. DODIG May 31, Defense Departmental Reporting System-Budgetary Was Not Effectively Implemented for the Army General Fund

E m e rgency Health S e r v i c e s Syste m M o d e r n i zation

MENTOR-CONNECT TUTORIAL

Good Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center

Completing E2B(R3) Compliance in Total Safety 7

General Administration GA STANDARD OPERATING PROCEDURE ON SOPs: Preparing, Maintaining and Training

Strategic Plan May 4, 2017

November 7, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

The Prescription Drug User Fee Act (PDUFA): Background and Issues for PDUFA IV Reauthorization

29A: Hours may be used as the Base labor increment. 28Q: Are human in the loop solutions of interest for ASKE? 28A: Yes

SMALL CITY PROGRAM. ocuments/forms/allitems.

PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS

CAQH CORE and ehealth Initiative Joint Webinar

Transcription:

PDUFA IV Information Technology Plan Armando Oliva, M.D. Deputy Director for Bioinformatics Office of Critical Path Programs FDA

Outline What is the PDUFA IV IT Plan? What does it say? How can CDISC and FDA work together to achieve success?

What is it? Rolling 5-year plan how FDA will automate business processes and develop IT systems to support other PDUFA IV performance goals Published early Jan 2008 in draft Public Comment period now closed Finalize by May 2008 Updated Periodically Helps industry align their IT investments with those of the Agency

How did it come about? From PDUFA and the PDUFA IV Goals Letter PDUFA Prescription Drug User Fee Act fee for service Re-authorized in 2007 for another 5 years PDUFA IV FDA services are described in the PDUFA IV Goals Letter letter from Secretary of HHS to Congress

PDUFA IV Goals Letter FDA agrees to meet certain I.T. goals: http://www.fda.gov/oc/pdufa4/pdufa4goals.html 1. FDA will develop and periodically update a five-year IT plan for improving the automation of business processes and acquiring and maintaining information systems to achieve the objectives defined above in PDUFA IT Goal A. The plan will include measurable or observable milestones toward achievement of those objectives. 2. The IT plan will be reviewed and approved through the appropriate FDA governance process to ensure it conforms to the Agency s overall long-term automation strategy. 3. The IT plan will be drafted, published on the FDA web site, and updated as follows: a) FDA will publish a draft of the IT plan by December 31, 2007. At that time, FDA will solicit and consider comments from the public on the draft IT plan. The public comment period will be at least 45 calendar days. FDA will complete revisions to the IT plan and publish the final version no later than May 30, 2008. b) FDA will conduct an annual assessment of progress against the IT plan and publish on the FDA web site a summary of the assessment within 2 months after the close of each fiscal year. c) FDA will publish updates to the IT plan as FDA deems necessary to achieve the objectives defined in PDUFA IT Goal A. FDA will publish on the FDA web site draft revisions to the IT plan; solicit comments from the public on those draft revisions; and consider the public comments before completing and publishing updates to the IT plan.

What does it say? http://www.fda.gov/ohrms/dockets/dockets/07d0481/07d0481.html 37 pages Introduction Purpose Vision Goals and Objectives PDUFA IV IT Strategy Programs (Pre-market, Post-market) Appendices (actual Projects / Initiatives)

Projects Related to CDISC Proposed Rule: Submission of Standardized Electronic Study Data from Clinical Studies Evaluating Human Drugs and Biologics Data Standards (p. 23): CDISC for standardized clinical and non-clinical study data content (semantics) HL7 XML for standardized exchange format for all structured regulatory product data (syntax) FDA CDISC Communications Team (p. 23) ensure that CDISC standards meet FDA scientific requirements

Target Data Flow (p. 23) Site Sponsor CDISC Content and Interchange Interchange: HL7 output file CDISC Content Trial Design CDASH Data Checker and Loader FDA Reviewers Sponsor Data Warehouse (ODM) SDTM ADaM Site Data Archive (ODM) MedWatch AE Reports (ICSR) Janus FDA/NCI Analytical Data Warehouse Review Tools

Projects CDSIC-HL7 Project HL7 XML messages for CDISC content BRIDG Harmonize all CDISC content in BRIDG Janus study data warehouses (NCI, NCTR) Phase 3 pilot: loading more data, standard terminology/nci EVS, test loading of CDISC-HL7 messages SEND Phase 2 pilot: accept, load nonclinical data into NCTR Janus ecrf Pilot (ODM) develop ODM ecrf viewer CDASH FDA playing a supporting role

CDISC FDA Collaboration Key to Success CDISC-FDA Communications Team Enhance/Improve SDTM SDTM critical for the development of standard analytic algorithms and review tools of the future Need more and more consistent FDA involvement in CDISC processes Continued FDA-CDISC joint involvement in HL7 and BRIDG CDISC Support for ongoing FDA projects and pilots much appreciated FDA Staff Training Efforts very popular!!